Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

Saffron crop washed out in Jammu & Kashmir floods

The crop is grown on small land holdings with an average size of 0.5 hectare by some 16,000 families in 226 villages

Iron ore prices surge to 4-year high at Odisha auction

The quoted price is nearly 45% more than the highest selling price of Rs 3,526 per tonne in the previous quarter (July-September) and 62% higher ...

FTIL opposes any move for NSEL amalgamation

FTIL says FMC proposal in this regard is not in public interest and ignores what has been found and accomplished in addressing the payments ...

Today's picks - 16 September 2014

Nifty, Bank Nifty, ITC, DLF & Tata Steel

Shemaroo IPO subscribed 27%

Shemaroo Entertainment's Rs 120 crore initial public offering (IPO) has received 27% subscription on day one

Back to Top